03 Experimental Therapeutics Program

03实验治疗（ET） 摘要 实验治疗学（ET）计划是UAB的主要转化/临床研究引擎 CCC. ET计划的主要目标是开发新的治疗策略， 患者的治愈机会增加，如果未治愈，生存时间延长，则增加 无疾病进展，以及癌症相关症状的改善和缓解（改善 生活质量）。追求这一总目标涉及三个科学目标：（1）促进和实施 涉及基础科学家和临床教师的转化临床试验和临床前研究，（2）促进 发现和验证可以帮助癌症诊断/预后的生物标志物， 响应和选择最有可能从治疗方式中受益的人群，以及（3）促进 开发可整合到临床前和转化临床的新型成像技术 问题研究这些科学目标得到了积极的SPORE资助（脑、乳腺、胰腺和 宫颈癌）和苏珊G。科门的治愈承诺基金此外，还有一个 与南方研究（SR）在药物发现方面的科学合作显著扩大， 开发和HudsonAlpha生物技术研究所的高通量基因测序。药物 通过第一阶段临床试验的正式化，增强了ET计划的发现工作 计划，并实施了亚拉巴马药物发现联盟（ADDA）。强大的合作与 其他的国家研究小组已经成立，包括转化乳腺癌研究 联合会（TBCRC）和国家合作小组通过NCI U10-NCTC领导学术 合作网站授权。回旋加速器的获得和实施增加了重大的临床前和 临床PET研究能力的计划。最近的关键招聘大大提高了临床 在过去的两年里，试行和应计。ET计划继续增长， 会员资格、研究预算和治疗试验的应计费用。ET计划的主要教师代表 13个部门，4所学校，SR和HudsonAlpha，总成员从2011年的62名教师增加到 2015年69。研究预算总额从2011年的10，994，390美元年度直接费用增加到2012年的10，994，390美元。 2015年的年度直接费用为11，222，026美元（2，450，158美元来自国家癌症研究所[NCI]，3，473，522美元来自 其他同行评审，以及4，588，101百万美元的行业年度直接研究支持）。患者累积至 在过去四年的资助期内，共有1，717名患者参加了治疗试验，其中32%的患者 药物启动的试验，28%的试验/I期研究，33%的II期试验。该计划有426 过去五年供资期间的出版物，包括27%的方案间出版物和29%的方案内出版物 程序性著作权

03 EXPERIMENTAL THERAPEUTICS (ET) PROGRAM ABSTRACT The Experimental Therapeutics (ET) Program is the major translational/clinical research engine of the UAB CCC. The main objective of the ET Program is to develop novel therapeutic strategies that will provide cancer patients with an enhanced opportunity for cure and, if not cured, with an improved survival time, increased freedom from disease progression, and an improvement and relief of cancer-associated symptoms (improved quality of life). The pursuit of this overall objective involves three scientific aims: (1) to promote and implement translational clinical trials and preclinical research involving basic scientists and clinical faculty, (2) to promote discovery and validation of biomarkers that can aid in cancer diagnosis/prognosis, prediction of therapeutic response and selection of populations most likely to benefit from treatment modalities, and (3) to promote development of novel imaging technology that can be integrated into pre-clinical and translational clinical studies. These scientific goals have been enhanced by active SPORE funding (Brain, Breast, Pancreas, and Cervical cancers) and The Susan G. Komen for the Cure Promise Grant. In addition, there has been a significant expansion in scientific collaborations with Southern Research (SR) for drug discovery and development and HudsonAlpha Institute for Biotechnology for high-throughput genetic sequencing. The drug discovery efforts of the ET Program have been enhanced by the formalization of the Phase I Clinical trials Program, and the implementation of the Alabama Drug Discovery Alliance (ADDA). Strong collaborations with other national research groups have been established including the Translational Breast Cancer Research Consortium (TBCRC) and the National Cooperative Groups through the NCI U10-NCTC Lead Academic Partnership Site grant. The acquisition and implementation of the cyclotron has added major pre-clinical and clinical PET research capabilities to the program. Recent key recruitments have significantly enhanced clinical trial implementation and accrual over the last two years. The ET program has continued to grow in membership, research budget, and accrual to therapeutic trials. Primary faculty in the ET Program represent 13 departments, 4 schools, SR and HudsonAlpha, with total membership increasing from 62 faculty in 2011 to 69 in 2015. The overall research budget has increased from $10,994,390 annual direct costs in 2011 to $11,222,026 annual direct costs in 2015 ($2,450,158 from the National Cancer Institute [NCI], $3,473,522 of other peer-reviewed, and $4,588,101 million in Industry annual direct research support). Patient accrual to therapeutic trials over the past four year funding period was 1,717 patients, including 32% accrual to investigator-initiated trials, 28% to pilot/phase I studies, and 33% to phase II trials. The program had 426 publications over the past five year funding period including 27% inter-programmatic and 29% intra- programmatic authorship.